LKB1 gene inactivation does not sensitize non-small cell lung cancer cells to mTOR inhibitors in vitro

被引：0
|
作者：
Ping Xiao
Lin-lin Sun
Jing Wang
Rui-li Han
Qing Ma
Dian-sheng Zhong
机构：
[1] Tianjin Medical University General Hospital,Department of Oncology
[2] Tianjin Lung Cancer Institute,undefined
[3] Tianjin Medical University General Hospital,undefined
来源：
Acta Pharmacologica Sinica | 2015年 / 36卷
关键词：
non small-cell lung cancer; mTOR protein; liver kinase B1; AKT; rapamycin; RAD001; LY294002;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1107 / 1112
页数：5
相关论文
共 50 条
  • [41] LKB1 deficiency is associated with a unique metabolic signature in Kras mutant non-small cell lung cancer (NSCLC)
    Liu, Tingyu
    Sennott, Erin
    Zhong, Zhengjie
    Steadman, Mya
    Marsh, Kelly
    Hurov, Jonathan
    Benes, Cyril
    Engelman, Jeffrey A.
    CANCER RESEARCH, 2016, 76
  • [42] Prognostic Impact of LKB1 Expression in Advanced Non-Small-Cell Lung Cancer
    Diaz-Garcia, D. A.
    Ramirez Tirado, L. A.
    Aviles-Salas, A.
    Cardona, A. F.
    Rodriguez-Rios, A.
    Barron, F.
    Arrieta, O. G.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S780 - S781
  • [43] 2-Deoxyglucose Suppresses ERK Phosphorylation in LKB1 and Ras Wild-Type Non-Small Cell Lung Cancer Cells
    Sun, Linlin
    Liu, Xiuju
    Fu, Haian
    Zhou, Wei
    Zhong, Diansheng
    PLOS ONE, 2016, 11 (12):
  • [44] Effect of LKB1 activity on the sensitivity to PI3K/mTOR inhibitor in non-small-cell lung cancer
    Shukuya, Takehito
    Yamada, Tadaaki
    Koenig, Michael J.
    Rahman, Mohammad A.
    Amann, Joseph M.
    Carbone, David P.
    CANCER RESEARCH, 2017, 77
  • [45] Identifying therapy responsive and resistant LKB1 mutant non-small cell lung tumor populations
    Abt, Evan
    Momcilovic, Milica
    Seki, Atsuko
    McMickle, Robert
    Stout, David
    Fishbein, Michael C.
    Shackelford, David B.
    CANCER RESEARCH, 2014, 74 (19)
  • [46] Human non-small cell lung cancer (NSCLC) cell lines with inactivated LKB1 and KRAS mutations are sensitive to MEK inhibition
    Mahoney, C.
    Choudhury, B.
    Davies, H.
    Bignell, G.
    Stratton, M.
    Futreal, A.
    EJC SUPPLEMENTS, 2008, 6 (09): : 32 - 33
  • [47] Mutant LKB1 Confers Enhanced Radiosensitization in Combination with Trametinib in KRAS-Mutant Non-Small Cell Lung Cancer
    Wang, Yifan
    Li, Nan
    Jiang, Wen
    Deng, Weiye
    Ye, Rui
    Xu, Cai
    Qiao, Yawei
    Sharma, Amrish
    Zhang, Ming
    Hung, Mien-Chie
    Lin, Steven H.
    CLINICAL CANCER RESEARCH, 2018, 24 (22) : 5744 - 5756
  • [48] LKB1/STK11 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value
    Facchinetti, Francesco
    Bluthgen, Maria Virginia
    Tergemina-Clain, Gabrielle
    Faivre, Laura
    Pignon, Jean-Pierre
    Planchard, David
    Remon, Jordi
    Soria, Jean-Charles
    Lacroix, Ludovic
    Besse, Benjamin
    LUNG CANCER, 2017, 112 : 62 - 68
  • [49] LKB1 Expression Correlates with Increased Survival in Patients with Advanced Non-Small Cell Lung Cancer Treated with Chemotherapy and Bevacizumab
    Bonanno, Laura
    De Paoli, Angela
    Zulato, Elisabetta
    Esposito, Giovanni
    Calabrese, Fiorella
    Favaretto, Adolfo
    Santo, Antonio
    Del Conte, Alessandro
    Chilosi, Marco
    Oniga, Francesco
    Sozzi, Gabriella
    Moro, Massimo
    Ciccarese, Francesco
    Nardo, Giorgia
    Bertorelle, Roberta
    Candiotto, Cinzia
    De Salvo, Gian Luca
    Amadori, Alberto
    Conte, PierFranco
    Indraccolo, Stefano
    CLINICAL CANCER RESEARCH, 2017, 23 (13) : 3316 - 3324
  • [50] Genetic variants in LKB1/AMPK/mTOR pathway are associated with clinical outcomes of chemotherapy in non-small cell lung cancer (vol 13, pg 3322, 2022)
    Choi, S. H.
    Do, S. K.
    Lee, S. Y.
    Choi, J. E.
    Kang, H-G
    Hong, M. J.
    THORACIC CANCER, 2023,
12345